our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CREB3L1 expression
i
Other names: CREB3L1, CAMP Responsive Element Binding Protein 3 Like 1, OASIS, Cyclic AMP-Responsive Element-Binding Protein 3-Like Protein 1, CAMP-Responsive Element-Binding Protein 3-Like Protein 1, Old Astrocyte Specifically-Induced Substance, BBF-2 Homolog (Drosophila), BBF-2 Homolog
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Specific removal of this hypermethylation in glioblastomas transplanted into nude mice by epigenomic engineering suppresses the tumorigenesis. These findings suggest OASIS as a critical cell-cycle inhibitor with potential to act as a tumor suppressor.
11 months ago
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
Moreover, KPNA2 mediated the nuclear translocation of CREB3L1, thus allowing it to activate downstream ECM signaling. These results demonstrate that CREB3L1 maintains the CAF-like property of ATC cells by activating the ECM signaling, which remodels the tumor stromal microenvironment and drives the malignancy of ATC.
over 1 year ago
Journal
|
CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
These four drugs were: (1) palbociclib isethionate, a CDK4/6 inhibitor, (2) lanatocide C (also named isolanid), a Na+/K+-ATPase inhibitor, (3) cladribine, a nucleoside analog, and (4) homoharringtonine (also named omacetaxine mepesuccinate), a protein translation inhibitor. All four drugs were then separately evaluated for possible synergy with the chemotherapy agents, doxorubicin (an anthracycline) and paclitaxel (a microtubule stabilizing agent). A strong synergy was observed using the combination of homoharringtonine and paclitaxel, with high cytotoxicity towards TNBC cells at lower concentrations than when each was used separately.
over 1 year ago
Preclinical • Journal
|
CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
These results strongly support a metastasis suppressor role for CREB3L1 in human luminal A and TNBCs. Further, the ability to identify the subset of luminal A (7%) and TNBCs (75%) that are CREB3L1-deficient provides opportunities to stratify patients that would benefit from additional treatments to treat their more metastatic disease.
almost 2 years ago
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
Furthermore, U87-MG glioma cells were cultured in vitro and treated with different concentrations of ERS inducer thapsigargin (TG)...In conclusion, ERS may reduce the cell proliferative activity and promote apoptosis through mediating CREB3L1 expression. CREB3L1 may be a novel potential target for glioma therapy.
2 years ago
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)
This combination treatment was also effective in mediating nuclear translocation of CREB3L1 in cancer cells isolated from ovarian tumor biopsies at different stages of disease progression. The measurement of CREB3L1 expression in clinical specimens of ovarian cancer revealed lack of correlation with the stage of disease progression, suggesting that understanding the mechanisms of nuclear accumulation of CREB3L1 after doxorubicin treatment alone or in combination with oncolytic virotherapy may lead to the development of more effective treatment strategies against ovarian cancer.
over 2 years ago
Journal • Oncolytic virus • IO biomarker
|
CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1)